Henlius Announces Robust Growth and Strategic Advancements
Henlius, a global leader in biopharmaceuticals, recently revealed its impressive interim results for the year 2025. With a steady revenue stream, the first half of the year marked a significant leap in overall financial performance. The company reported a revenue of approximately RMB2.8195 billion, showcasing a 2.7% year-over-year growth, while its gross profit reached RMB2.1992 billion, reflecting a robust 10.5% increase compared to the previous year. Net profit stood at RMB390.1 million. A particular highlight was the company's remarkable operating cash flow, which surged by 206.8% year-on-year to RMB770.9 million. This solid performance underscores Henlius' commitment to enhancing its global footprint and driving sustainable innovation.
Surge in Overseas Product Profits Catalyzes Growth
Perhaps the most exciting aspect of Henlius’ performance is its substantial growth in overseas profits, which saw an astonishing increase of over 200%. The company has successfully established itself in various international markets with its commercialized products. In line with this, the cash inflows from business development agreements surpassed RMB1 billion, marking a staggering 280% growth year-on-year. As Henlius continues to expand its global reach, it anticipates significant contributions from its overseas revenue streams for the remainder of 2025, predicting accelerated momentum into 2026.
Continued Investment in Research and Development
Henlius has made substantial strides in its R&D investments, committing RMB995.4 million during this reporting period, a 21.3% increase year-on-year. This focus is directed primarily towards the preclinical development of advanced innovative molecules. The company is dedicated to enhancing its R&D ecosystem, aiming to bolster its capabilities in delivering top-quality, patient-centered biological treatments.
Strategic Global Expansion Efforts
Currently, Henlius boasts a diverse portfolio of six products launched in the local market, alongside four more approved for use in international territories, effectively reaching over 850,000 patients across approximately 60 markets globally. The ongoing expansion not only boosts Henlius' market presence but also signifies a growing need for innovative solutions in oncology and autoimmune disease treatments. There is an increasing focus on developing a pipeline of differentiated therapies, especially potential best-in-class (BIC) and first-in-class (FIC) candidates, ensuring a comprehensive approach to addressing unmet medical needs.
Noteworthy Product Innovations and Approvals
One of Henlius' standout products, serplulimab—trademarked HANSIZHUANG in local markets and Hetronifly abroad—has made significant strides, being recognized as the first anti-PD-1 monoclonal antibody approved for the initial treatment of small cell lung cancer. In the past half-year alone, serplulimab achieved global sales revenue of RMB597.7 million, with recent approvals in critical markets such as Europe, Singapore, Malaysia, and India. The expansion of serplulimab into nearly 40 countries provides a potential reach to half the world's population. Additionally, the company is making moves to submit a Biologics License Application (BLA) to the FDA in the forthcoming year, aiming to enhance accessibility to this vital treatment for patients in the U.S.
Continued Growth in Innovative Portfolio
Henlius is focusing keenly on its breast cancer product, HANQUYOU. The company reported a global income of RMB1.4442 billion from this innovative treatment in the first half of 2025. Recently approved in new markets including Mexico, this product has now obtained approvals in over 50 countries. In addition to HANQUYOU, Henlius is actively developing additional therapies targeting various cancers, including multiple new drugs currently under evaluation.
Future Development Plans and Hospital Collaborations
Henlius aims to continue strengthening its market position by entering into key partnerships with healthcare stakeholders and collaborative ventures. By leveraging its advanced technologies and broad resource network, the company is poised to accelerate its development of cutting-edge therapies further. Notably, Henlius is dedicated to optimizing its overall operational frameworks—including R&D, regulatory, and commercialization practices—to maintain its competitive advantage as a biopharmaceutical innovator.
About Henlius
Founded in 2010, Henlius (2696.HK) has rapidly evolved into a well-respected biopharmaceutical company focused on producing affordable, high-quality biologic medicines. With an extensive product pipeline and strong emphasis on innovation in oncology, autoimmune, and ophthalmic diseases, Henlius aims to meet the diverse healthcare needs of patients worldwide. Its integrated biopharmaceutical platform continues to support unique advancements in drug development, thereby fulfilling its mission to elevate global health standards.
Frequently Asked Questions
What kind of growth did Henlius achieve in the first half of 2025?
Henlius reported a revenue of approximately RMB2.8195 billion, showing a 2.7% increase year over year, alongside a 10.5% growth in gross profit.
How much did Henlius invest in R&D during the reporting period?
The company invested RMB995.4 million in R&D, marking a 21.3% increase compared to the previous year.
What products has Henlius launched in international markets?
Henlius has launched six products in China and four in international markets, reaching about 60 countries.
What is the significance of serplulimab for Henlius?
Serplulimab is Henlius' key product, with global sales reaching RMB597.7 million, and it is the first anti-PD-1 antibody approved for small cell lung cancer treatment.
What are Henlius' future plans for product approvals?
Henlius plans to submit a Biologics License Application to the FDA for serplulimab and is focused on further expanding its product portfolio in various oncology fields.
